// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial

Toby Maher - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Nintedanib

Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil

Eric White - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Nintedanib

Late Breaking Abstract - A PET imaging study to confirm target engagement in the lungs of patients with IPF following a single dose of a novel inhaled avß6 integrin inhibitor

Toby Maher - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Late Breaking Abstract - Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry demonstrates inhaled drug deposition in transbronchial cryobiopsy samples of patients with Interstitial Lung Disease (ILD)

Theresia Mikolasch - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

Atrovent

Late Breaking Abstract - The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey

Argyris Tzouvelekis - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Idiopathic pulmonary fibrosis

N/A

Fewer and smaller airways in COPD subjects measured by CT imaging

Kristoffer Ostridge - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Utility of computed tomography (CT) to predict need for early surgery and recurrence after first episode of primary spontaneous pneumothorax (PSP)

Asif Mahmood Azam - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Primary spontaneous pneumothorax

N/A

A low cost, easily implementable method of shortening patient pathways in imaging incidentally suspicious for lung malignancy

Simon Biart - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Novel quantitative bronchiectasis scoring technique for chest computed tomography: BEST-CT. A study within the iABC project

Jennifer Meerburg - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Tobramycin

Lung deposition of extrafine vs non-extrafine triple therapies in patients with COPD using Functional Respiratory Imaging (FRI)

Eva Topole - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Hyperpolarised 129-xenon diffusion-weighted MRI in interstitial lung disease

James Eaden - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Extrinsic allergic alveolitis

N/A

Longitudinal change in hyperpolarised 129-xenon MR spectroscopy in interstitial lung disease

James Eaden - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Extrinsic allergic alveolitis

N/A

Predicting multiple breath washout outcomes from hyperpolarised gas magnetic resonance imaging (MRI)

Carl Whitfield - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Cystic Fibrosis

N/A

Assessing ventilation/perfusion properties with dynamic 19F-MRI of inhaled perfluoropropane

Benjamin Pippard - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Perflutren

Compressed sensing to reduce breath-hold duration in 19F-MR ventilation imaging

Benjamin Pippard - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Free breathing lung MRI T1 in patients with idiopathic pulmonary fibrosis and healthy volunteers

Laura Saunders - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Correlations of ventilation heterogeneity and spirometry in asthma; initial experience with hyperpolarised gas MRI in a clinical setting

Grace Mussell - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Repeatability and Sensitivity to change of right ventricular analysis methods using cardiac magnetic resonance imaging in PAH: results from the RESPIRE Study

Andy Swift - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Using an upright MRI system to assess the impact of posture on diaphragm morphology

Shahideh Safavi - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Imaging functional and microstructural changes in the lungs of children born prematurely

James M. Wild - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved